BELLINGER ANDREW (Chief Scientific Officer) sold 60.1% of their position (10K shares) of VERVE THERAPEUTICS, INC. on the open market
Open‑market sale worth $249.0K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 7/15/2022ACC: 0001209191-22-042264
Officer· Chief Scientific Officer
Since Jun 2021
-10K
Net shares
Net seller
$249.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
10K acquired · 20K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+10K
Price / share
$1.48
Trade value
$14.80K
% of position
150.9%
7/13/2022
6.63K→16.63K
Common Stock
Direct
Shares
−10K
Price / share
$24.90
Trade value
$249K
% of position
60.1%
7/13/2022
16.63K→6.63K
Total
Net shares
+0.00
Net value
-$234.20K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/13/2022 | M · Option Exercise | +10K | $1.48 | $14.80K | 150.9% | 6.63K | 16.63K |
| Common Stock Direct | 7/13/2022 | S · Sale | −10K | $24.90 | $249K | 60.1% | 16.63K | 6.63K |
| Total | +0.00 | -$234.20K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
10K shares
Shares
−10K
Strike price
1.48
Held after
137K
Exercisable
—
7/13/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock10K shares | 7/13/2022 | M · Option Exercise | −10K | 1.48 | — | 137K |